680 filings
Page 9 of 34
8-K
fkwf90z
2 Mar 18
Departure of Directors or Certain Officers
12:00am
8-K
jk1g3js fxhc
22 Feb 18
HEPLISAV-B is the First and Only Two-Dose Vaccine in the U.S. for Hepatitis B Prevention in Adults
12:00am
8-K
txvpvd9rif4 wr
20 Feb 18
Dynavax Secures $175 Million inNon-Dilutive Debt Financing
12:00am
8-K
3vf92aosxd
9 Jan 18
Dynavax Announces HEPLISAV-B™ is Now Available in the United States
12:00am
8-K
dc87pc qx8rgxk
5 Jan 18
Results of Operations and Financial Condition
12:00am
S-8
mefigzt lx00w
30 Nov 17
Registration of securities for employees
12:00am
8-K
j0rzi3in3n 7m
30 Nov 17
Departure of Directors or Certain Officers
12:00am
8-K
kl2gts4eeva1h1ze2 db
14 Nov 17
Entry into a Material Definitive Agreement
12:00am
8-K
s95a4c
3 Nov 17
Dynavax Reports Third Quarter 2017 Financial Results
12:00am
424B5
rx94gddm1
3 Nov 17
Prospectus supplement for primary offering
12:00am
8-K
7smt9 70ezveaik6
1 Sep 17
Other Events
12:00am
424B5
fto0p
10 Aug 17
Prospectus supplement for primary offering
12:00am
8-K
gkdbu
10 Aug 17
Entry into a Material Definitive Agreement
12:00am
S-3ASR
1ytxv6yg1bpf391szss0
8 Aug 17
Automatic shelf registration
12:00am
424B5
hml7 xnv6n
8 Aug 17
Prospectus supplement for primary offering
12:00am
8-K
zayu7rwnm6t 88h3vjgc
7 Aug 17
Dynavax Provides U.S. Regulatory Update onHEPLISAV-B™ Following FDA Advisory Committee Meeting
12:00am
8-K
9i4apqkrrjbpglb
2 Aug 17
Dynavax Reports Second Quarter 2017 Financial Results
12:00am
8-K
2251z9wgi
31 Jul 17
Dynavax Announces FDA Advisory Committee
12:00am